Efferent visual dysfunction from multiple sclerosis

International Ophthalmology Clinics

Volumn 47, Issue 4, 2007, Pages 1-13

  Rucker, Janet C ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; 4 AMINOPYRIDINE; BACLOFEN; CLONAZEPAM; GABAPENTIN; MEMANTINE; VALPROIC ACID; VIGABATRIN;

ALZHEIMER DISEASE; ATAXIA; BACKACHE; BINOCULAR CONVERGENCE; CLINICAL FEATURE; CLINICAL TRIAL; CONFUSION; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; EYE EXAMINATION; EYE MOVEMENT; FATIGUE; HEADACHE; HUMAN; INSOMNIA; INTERNUCLEAR OPHTHALMOPLEGIA; MOTOR SYSTEM; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SEIZURE; SINGLE DRUG DOSE; SOMNOLENCE; TREMOR; VISUAL IMPAIRMENT; WEAKNESS; ANIMAL; EYE MOVEMENT DISORDER; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS;

ANIMALS; EYE MOVEMENTS; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; OCULAR MOTILITY DISORDERS; PROGNOSIS;

EID: 38449096654     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/IIO.0b013e318157259e     Document Type: Review

References (54)

1. Leigh RJ, Zee DS. The Neurology of Eye Movements. 4th ed. New York: Oxford University Press; 2006.
2. Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005;4:111-121.
3. Weinshenker BG, Rice GP, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain. 1991;114(Pt 2):1045-1056.
4. Downey DL, Stahl JS, Bhidayasiri R, et al. Saccadic and vestibular abnormalities in multiple sclerosis: sensitive clinical signs of brainstem and cerebellar involvement. Ann N Y Acad Sci. 2002;956:438-440.
5. Derwenskus J, Rucker JC, Serra A, et al. Abnormal eye movements predict disability in MS: two-year follow-up. Ann N Y Acad Sci. 2005;1039:521-523.
6. Muri RM, Meienberg O. The clinical spectrum of internuclear ophthalmoplegia in multiple sclerosis. Arch Neurol. 1985;42:851-855.
7. Frohman EM, Zhang H, Kramer PD, et al. MRI characteristics of the MLF in MS patients with chronic internuclear ophthalmoparesis. Neurology. 2001;57:762-768.
8. Crane TB, Yee RD, Baloh RW, et al. Analysis of characteristic eye movement abnormalities in internuclear ophthalmoplegia. Arch Ophthalmol. 1983;101:206-210.
9. Frohman TC, Frohman EM, O'Suilleabhain P, et al. Accuracy of clinical detection of INO in MS: corroboration with quantitative infrared oculography. Neurology. 2003;61:848-850.
10. Chen CM, Lin SH. Wall-eyed bilateral internuclear ophthalmoplegia from lesions at different levels in the brainstem. J Neuro-ophthalmol. 2007;27:9-15.
11. Ranalli PJ, Sharpe JA. Vertical vestibulo-ocular reflex, smooth pursuit and eye-head tracking dysfunction in internuclear ophthalmoplegia. Brain. 1988;111(Pt 6):1299-1317.
12. Evinger LC, Fuchs AF, Baker R. Bilateral lesions of the medial longitudinal fasciculus in monkeys: effects on the horizontal and vertical components of voluntary and vestibular induced eye movements. Exp Brain Res. 1977;28:1-20.
13. Zee DS, Hain TC, Carl JR. Abduction nystagmus in internuclear ophthalmoplegia. Ann Neurol. 1987;21:383-388.
14. Baloh RW, Yee RD, Honrubia V. Internuclear ophthalmoplegia. I. Saccades and dissociated nystagmus. Arch Neurol. 1978;35:484-489.
15. Carpenter MB, Strominger NL. The medial longitudinal fasciculus and disturbances of conjugate horizontal eye movements in the monkey. J Comp Neurol. 1965;125:41-65.
16. Gamlin PD, Gnadt JW, Mays LE. Lidocaine-induced unilateral internuclear ophthalmoplegia: effects on convergence and conjugate eye movements. J Neurophysiol. 1989;62:82-95.
17. Kupfer C, Cogan DG. Unilateral internuclear ophthalmoplegia. A clinicopathological case report. Arch Ophthalmol. 1966;75:484-489.
18. Leigh RJ, Wolinsky JS. Keeping an eye on MS. Neurology. 2001;57:751-752.
19. Gawne-Cain ML, O'Riordan JI, Coles A, et al. MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences. J Neurol Neurosurg Psychiatry. 1998;64:197-203.
20. Straube A, Leigh RJ, Bronstein A, et al. EFNS task force - therapy of nystagmus and oscillopsia. Eur J Neurol. 2004;11:83-89.
21. Rucker JC. Current treatment of nystagmus. Curr Treat Options Neurol. 2005;7:69-77.
22. Barton JJ, Cox TA. Acquired pendular nystagmus in multiple sclerosis: clinical observations and the role of optic neuropathy. J Neurol Neurosurg Psychiatry. 1993;56:262-267.
23. Averbuch-Heller L, Zivotofsky AZ, Das VE, et al. Investigations of the pathogenesis of acquired pendular nystagmus. Brain. 1995;118(Pt 2):369-378.
24. Buttner-Ennever JA, Horn AK. Pathways from cell groups of the paramedian tracts to the floccular region. Ann N Y Acad Sci. 1996;781:532-540.
25. Lopez LI, Bronstein AM, Gresty MA, et al. Clinical and MRI correlates in 27 patients with acquired pendular nystagmus. Brain. 1996;119(Pt 2):465-472.
26. Gresty MA, Ell JJ, Findley LJ. Acquired pendular nystagmus: its characteristics, localising value and pathophysiology. J Neurol Neurosurg Psychiatry. 1982;45:431-439.
27. Aschoff JC, Conrad B, Kornhuber HH. Acquired pendular nystagmus with oscillopsia in multiple sclerosis: a sign of cerebellar nuclei disease. J Neurol Neurosurg Psychiatry. 1974;37:570-577.
28. Das VE, Oruganti P, Kramer PD, et al. Experimental tests of a neural-network model for ocular oscillations caused by disease of central myelin. Exp Brain Res. 2000;133:189-197.
29. Averbuch-Heller L, Tusa RJ, Fuhry L, et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol. 1997;41:818-825.
30. Bandini F, Castello E, Mazzella L, et al. Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: how valid is the GABAergic hypothesis? J Neurol Neurosurg Psychiatry. 2001;71:107-110.
31. Starck M, Albrecht H, Pollmann W, et al. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol. 1997;244:9-16.
32. Tomsak RL, Dell'Osso LF, Rucker JC, et al. Treatment of acquired pendular nystagmus from multiple sclerosis with eye muscle surgery followed by oral memantine. In: Digital Journal of Ophthalmology: Harvard University; 2005.
33. Shery T, Proudlock FA, Sarvananthan N, et al. The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study. Br J Ophthalmol. 2006;90:839-843.
34. Ito M, Nisimaru N, Yamamoto M. Specific patterns of neuronal connexions involved in the control of the rabbit's vestibulo-ocular reflexes by the cerebellar flocculus. J Physiol. 1977;265:833-854.
35. Leigh RJ. Potassium channels, the cerebellum, and treatment for downbeat nystagmus. Neurology. 2003;61:158-159.
36. Strupp M, Schuler O, Krafczyk S, et al. Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology. 2003;61:165-170.
37. Etzion Y, Grossman Y. Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cells. Exp Brain Res. 2001;139:419-425.
38. Waespe W, Cohen B, Raphan T. Dynamic modification of the vestibulo-ocular reflex by the nodulus and uvula. Science. 1985;228:199-202.
39. Tan E, Kansu T. Bilateral horizontal gaze palsy in multiple sclerosis. J Clin Neuro-ophthalmol. 1990;10:124-126.
40. Milea D, Napolitano M, Dechy H, et al. Complete bilateral horizontal gaze paralysis disclosing multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;70:252-255.
41. Slyman JF, Kline LB. Dorsal midbrain syndrome in multiple sclerosis. Neurology. 1981;31:196-198.
42. Quint DJ, Cornblath WT, Trobe JD. Multiple sclerosis presenting as Parinaud syndrome. Am J Neuroradiol. 1993;14:1200-1202.
43. Lee WB, Berger JR, O'Halloran HS. Parinaud syndrome heralding MS. Neurology. 2003;60:322.
44. Frohman EM, Dewey RB, Frohman TC. An unusual variant of the dorsal midbrain syndrome in MS: clinical characteristics and pathophysiologic mechanisms. Mult Scler. 2004;10:322-325.
45. Francis DA, Heron JR. Ocular flutter in suspected multiple sclerosis: a presenting paroxysmal manifestation. Postgrad Med J. 1985;61:333-334.
46. Schon F, Hodgson TL, Mort D, et al. Ocular flutter associated with a localized lesion in the paramedian pontine reticular formation. Ann Neurol. 2001;50:413-416.
47. Sandramouli S, Benamer HT, Mantle M, et al. See-saw nystagmus as the presenting sign in multiple sclerosis. J Neuro-ophthalmol. 2005;25:56-57.
48. Thomke F, Lensch E, Ringel K, et al. Isolated cranial nerve palsies in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997;63:682-685.
49. Beck RW, Cleary PA. Optic neuritis treatment trial. One-year follow-up results. Arch Ophthalmol. 1993;111:773-775.
50. Baier ML, Cutter GR, Rudick RA, et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology. 2005;64:992-995.
51. Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology. 1994;101:1771-1778.
52. Costello F, Coupland S, Hodge W, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol. 2006;59:963-969.
53. Sheliga BM, Chen KJ, Fitzgibbon EJ, et al. Initial ocular following in humans: a response to first-order motion energy. Vision Res. 2005;45:3307-3321.
54. Rucker JC, Sheliga BM, Fitzgibbon EJ, et al. Contrast sensitivity, first-order motion and Initial ocular following in demyelinating optic neuropathy. J Neurol. 2006;253:1203-1209.